Epithelial Cells and Provides a Regulatory Link to Lung Ephrin-A1 Suppresses Th2 Cell Activation

Total Page:16

File Type:pdf, Size:1020Kb

Epithelial Cells and Provides a Regulatory Link to Lung Ephrin-A1 Suppresses Th2 Cell Activation Ephrin-A1 Suppresses Th2 Cell Activation and Provides a Regulatory Link to Lung Epithelial Cells This information is current as Jan G. Wohlfahrt, Christian Karagiannidis, Steffen of October 2, 2021. Kunzmann, Michelle M. Epstein, Werner Kempf, Kurt Blaser and Carsten B. Schmidt-Weber J Immunol 2004; 172:843-850; ; doi: 10.4049/jimmunol.172.2.843 http://www.jimmunol.org/content/172/2/843 Downloaded from References This article cites 42 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/172/2/843.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Ephrin-A1 Suppresses Th2 Cell Activation and Provides a Regulatory Link to Lung Epithelial Cells1 Jan G. Wohlfahrt,* Christian Karagiannidis,* Steffen Kunzmann,* Michelle M. Epstein,† Werner Kempf,‡ Kurt Blaser,* and Carsten B. Schmidt-Weber2* Gene expression screening showed decreased ephrin-A1 expression in CD4؉ T cells of asthma patients. Ephrin-A1 is the ligand of the Eph receptor family of tyrosine kinases, forming the largest family of receptor tyrosine kinases. Their immune regulatory properties are largely unknown. This study demonstrates significantly reduced ephrin-A1 expression in T cells of asthma patients using real time-PCR. Immunohistological analyses revealed strong ephrin-A1 expression in lung tissue and low expression in cortical areas of lymph nodes. It is absent in T cell/B cell areas of the spleen. Colocalization of ephrin-A1 and its receptors was found only in the lung, but not in lymphoid tissues. In vitro activation of T cells reduced ephrin-A1 at mRNA and protein levels. T cell proliferation, activation-induced, and IL-2-dependent cell death were inhibited by cross-linking ephrin-A1, and not by Downloaded from engagement of Eph receptors. However, anti-EphA1 receptor slightly enhances Ag-specific and polyclonal proliferation of PBMC cultures. Furthermore, activation-induced CD25 up-regulation was diminished by ephrin-A1 engagement. Ephrin-A1 engagement reduced IL-2 expression by 82% and IL-4 reduced it by 69%; the IFN-␥ expression remained unaffected. These results demon- strate that ephrin-A1 suppresses T cell activation and Th2 cytokine expression, while preventing activation-induced cell death. The reduced ephrin-A1 expression in asthma patients may reflect the increased frequency of activated T cells in peripheral blood. That the natural ligands of ephrin-A1 are most abundantly expressed in the lung may be relevant for Th2 cell regulation in asthma and http://www.jimmunol.org/ Th2 cell generation by mucosal allergens. The Journal of Immunology, 2004, 172: 843–850. NA array-based screening of T cell cDNA of asthmatic group can bind several ephrins beside EphA1, which can bind only patients revealed reduced ephrin-A1 expression com- ephrin-A1 (2, 7). The ligands of the Eph receptor family have to be D pared with those of healthy donors (1). This finding is membrane bound to be active. Therefore, cell-cell interaction is interesting because ephrin-A1 expression was previously not re- necessary for Eph receptor-ephrin signaling, and soluble ephrins ϩ ported in peripheral CD4 T cells and in addition Eph receptors are active only if they are artificially clustered (9–11). are expressed on epithelial cells, which are important cells for the Characteristic for the ephrin biology is that not only is a forward lung function. Therefore, ephrins may represent a regulatory in- signaling pathway by the Eph receptors induced upon ligand bind- by guest on October 2, 2021 terface of epithelial surfaces in the lung and the immune system. ing but also the ligand itself transmits a reverse signals into the cell The ephrins are the ligands of the Eph receptors, which form (4). Interestingly, even the GPI-anchored ephrin-A ligands can in- with at least 14 members the largest group of tyrosine-kinase re- duce signals due to lipid raft microdomain-associated uncharac- ceptors (2–4). Ephrins are divided into two subclasses. The A terized receptors, which are specifically phosphorylated after eph- subclass (ephrin-A1–A6) consists of proteins tethered to the cell rin engagement (12–15). Involvement of Eph receptors and ephrins membrane via a GPI anchor, whereas the B subclass (ephrin-B1– is currently discussed in developmental processes (16–19), as well B3) consist of a transmembrane domain and a short cytoplasmic as their role in carcinogenesis (20). region (5, 6). Similarly, the Eph receptors are divided in an A Human ephrin-A1 is a 25-kDa glycoprotein with high homology (EphA1–9) and a B group (EphB1–6), dependent on the group of to murine and rat orthologs (21) and is abundantly expressed in ephrins they are binding. All Eph receptors of the A subclass can lung, but is also found in kidney, salivary gland, skin, and intestine bind ephrin-A1 (7), but the receptor EphA2 binds ephrin-A1 with (21, 22). It was found as an immediate-early response gene of ϭ the highest affinity (Kd 25 nM (8)). All receptors of the EphA endothelium induced by TNF-␣ (23) that possesses angiogenic and endothelial cell chemoattractant activity (24). EphA1 receptor is the least conserved member of the EphA receptor family and is * Swiss Institute of Allergy and Asthma Research, Davos, Switzerland; † Division of expressed in high levels in the liver, kidney, thymus, and lung but Immunology, Allergy and Infectious Disease, Department of Dermatology, Univer- sity of Vienna, Vienna, Austria; and ‡ Department of Dermatology, University Hos- not in the brain (25, 26). Eph receptors are also transcribed at high pital Zurich, Zurich, Switzerland. levels in tumor cells of epithelial origin (27, 28) and overproduc- Received for publication May 28, 2003. Accepted for publication November 4, 2003. tion of EphA1 induces tumorigenic ability of normal fibroblasts or The costs of publication of this article were defrayed in part by the payment of page melanoma progression (27, 29). This could support a role for charges. This article must therefore be hereby marked advertisement in accordance ephrins in the growth of the cells, but it could also indicate that the with 18 U.S.C. Section 1734 solely to indicate this fact. immune system recognizes the ephrin-overexpressing cells to a 1 This work was supported by Swiss National Foundation Grants 31.52986.97 and 31-65436.01, Roche Research Foundation Grant Mkl/stm 115-2001, the Gebert Ru¨f reduced degree. In fact, recent studies showed that immuno-com- Foundation Grant G-074/99, EMDO Foundation, Saurer Foundation, Zurich and OPO petent cells express Eph receptors and ephrin ligands. A soluble Foundation Zurich, Deutsche Forschungsgemeinschaft Grant KU 1403/1-1 (to splice variant of ephrin-A4 is secreted by activated human B lym- Z.S.K.). phocytes, and EphA2 receptors are present on dendritic cells/mac- 2 Address correspondence and reprint requests to Carsten B. Schmidt-Weber, Swiss Institute of Allergy and Asthma Research, Obere Strasse 22, CH-7270 Davos, Swit- rophages in tonsils (30) and peripheral blood (31). TCR engage- zerland. E-mail address: [email protected] ment along with EphB6 receptor cross-linking in the Jurkat cell Copyright © 2004 by The American Association of Immunologists, Inc. 0022-1767/04/$02.00 844 EPHRIN-A1 INHIBITS Th2 CELLS line results in FAS-mediated cell death (32). EphB6 receptor over- manufacturer. After hybridization, membranes were washed for 20 min with expression in this cell line suppresses TCR-mediated IL2 secretion 30 ml of a 0.1ϫ standard saline-citrate-phosphate/EDTA, 1% (w/v) SDS so- and CD25 expression by inhibition of the c-jun kinase pathway lution. Subsequently, moistened arrays were sealed in plastic bags and exposed for 24 h on phosphoimager screens (Fuji Film, Tokyo, Japan). The screens (33). Furthermore, plate-bound ephrin-A1 inhibits strong chemo- were analyzed using the FLA 3000 phosphoimager system (Fuji) and evalu- taxis in thymocytes and Jurkat cell line (34). These studies clearly ated with the AIDA program (Raytest, Urdorf, Switzerland). demonstrate that ephrins participate in immune regulation and pos- sibly convey an off signal to the immune system. T cell proliferation assay In this study, we describe ephrin-A1 expression by T cells and Triplicates of 1 ϫ 105 CD4ϩ T cells or PBMC were set up in 200 ␮lof the impact of ephrin-A1 cross-linking on T cell function. The RPMI 1640 in 96-well flat-bottom microtiter plates (Costar, Corning, NY). strong localized expression of Eph receptors on lung epithelia sug- Cells were activated by plate-bound mouse anti-human CD3 mAb (1 ␮g/ ml; clone CRL 8001; ATCC) and mouse anti-human CD28 mAb (2 ␮g/ml; gests that ephrins create microenvironmental conditions, which are clone 15E8; Netherlands Red Cross blood transfusion service). The bot- known to contribute to the pathogenesis of asthma such as hyper- toms of the wells were as well covered with rabbit Ig Fraction (DAKO- reactivity of the lung and airway remodeling. Cytomation, Zug, Switzerland), rabbit anti-human ephrin-A1 (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-human EphA1 receptor (R&D Materials and Methods Systems), or rabbit anti-human EphA2 receptor Abs (Sigma-Aldrich, Buchs, Switzerland).
Recommended publications
  • Ephrin-A4/Fc Chimera Human
    EPHRIN-A4 EXTRACELLULAR DOMAIN/FC CHIMERA Human, Recombinant Expressed in NSO mouse myeloma cells Product Number E 0403 Storage Temperature –20 °C Synonyms: LERK-4; EFL-4 Reagents Recombinant human Ephrin-A4 extracellular domain/Fc Product Description chimera is supplied as approximately 200 mg of protein Recombinant human Ephrin-A4 extracellular domain/Fc lyophilized from a sterile-filtered phosphate-buffered chimera consists of amino acid residues 1-171 saline (PBS) solution. 1 (extracellular domain of human Ephrin-A4) that was fused by means of a polypeptide linker to the Fc portion Preparation Instructions of human IgG1 that is 6X histidine-tagged at the Reconstitute the vial contents with sterile PBS. carboxyl terminus. The chimeric protein is expressed in Stock solution concentration should be no less than a mouse myeloma cell line, NSO. Recombinant Ephrin 100 µg/ml. A4 is a disulfide-linked homodimer. The amino terminus is Leu 26 determined by N-terminal Storage/Stability sequencing. The calculated molecular mass of the Lyophilized samples are stable for greater than six reduced protein is approximately 43.7 kDa, but as a months at –20 °C. Upon reconstitution, store at 2-4 °C result of glycosylation, the recombinant Ephrin-A4/Fc for up to one month. For extended storage, store in migrates as an approximately 50 kDa protein on working aliquots at –20 °C. Repeated freeze-thaw reducing SDS -PAGE. cycles should be avoided. Do not store in frost-free freezer. The Ephrin ligand family, of which Ephrin-A4 is a member, binds members of the Eph receptor family. All Product Profile ligands share a conserved extracellular sequence, Identity of Ephrin-A4/Fc was determined by western thought to correspond to the receptor binding domain.
    [Show full text]
  • Epha Receptors and Ephrin-A Ligands Are Upregulated by Monocytic
    Mukai et al. BMC Cell Biology (2017) 18:28 DOI 10.1186/s12860-017-0144-x RESEARCHARTICLE Open Access EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/ maturation and promote cell adhesion and protrusion formation in HL60 monocytes Midori Mukai, Norihiko Suruga, Noritaka Saeki and Kazushige Ogawa* Abstract Background: Eph signaling is known to induce contrasting cell behaviors such as promoting and inhibiting cell adhesion/ spreading by altering F-actin organization and influencing integrin activities. We have previously demonstrated that EphA2 stimulation by ephrin-A1 promotes cell adhesion through interaction with integrins and integrin ligands in two monocyte/ macrophage cell lines. Although mature mononuclear leukocytes express several members of the EphA/ephrin-A subclass, their expression has not been examined in monocytes undergoing during differentiation and maturation. Results: Using RT-PCR, we have shown that EphA2, ephrin-A1, and ephrin-A2 expression was upregulated in murine bone marrow mononuclear cells during monocyte maturation. Moreover, EphA2 and EphA4 expression was induced, and ephrin-A4 expression was upregulated, in a human promyelocytic leukemia cell line, HL60, along with monocyte differentiation toward the classical CD14++CD16− monocyte subset. Using RT-PCR and flow cytometry, we have also shown that expression levels of αL, αM, αX, and β2 integrin subunits were upregulated in HL60 cells along with monocyte differentiation while those of α4, α5, α6, and β1 subunits were unchanged. Using a cell attachment stripe assay, we have shown that stimulation by EphA as well as ephrin-A, likely promoted adhesion to an integrin ligand- coated surface in HL60 monocytes. Moreover, EphA and ephrin-A stimulation likely promoted the formation of protrusions in HL60 monocytes.
    [Show full text]
  • Ephrin-A1 Expression Contributes to the Malignant Characteristics of A
    843 HEPATOBILIARY DISEASE Ephrin-A1 expression contributes to the malignant Gut: first published as 10.1136/gut.2004.049486 on 11 May 2005. Downloaded from characteristics of a-fetoprotein producing hepatocellular carcinoma H Iida, M Honda, H F Kawai, T Yamashita, Y Shirota, B-C Wang, H Miao, S Kaneko ............................................................................................................................... Gut 2005;54:843–851. doi: 10.1136/gut.2004.049486 Background and aims: a-Fetoprotein (AFP), a tumour marker for hepatocellular carcinoma (HCC), is associated with poor prognosis. Using cDNA microarray analysis, we previously found that ephrin-A1, an angiogenic factor, is the most differentially overexpressed gene in AFP producing hepatoma cell lines. In the present study, we investigated the significance of ephrin-A1 expression in HCC. See end of article for Methods: We examined ephrin-A1 expression and its effect on cell proliferation and gene expression in authors’ affiliations five AFP producing hepatoma cell lines, three AFP negative hepatoma cell lines, and 20 human HCC ....................... specimens. Correspondence to: Results: Ephrin-A1 expression levels were lowest in normal liver tissue, elevated in cirrhotic tissue, and Dr S Kaneko, Department further elevated in HCC specimens. Ephrin-A1 expression was strongly correlated with AFP expression of Cancer Gene (r = 0.866). We showed that ephrin-A1 induced expression of AFP. This finding implicates ephrin-A1 in Regulation, Kanazawa University Graduate the mechanism of AFP induction in HCC. Ephrin-A1 promoted the proliferation of ephrin-A1 School of Medical Science, underexpressing HLE cells, and an ephrin-A1 antisense oligonucleotide inhibited the proliferation of 13-1 Takara-Machi, ephrin-A1 overexpressing Huh7 cells.
    [Show full text]
  • Engrailed and Fgf8 Act Synergistically to Maintain the Boundary Between Diencephalon and Mesencephalon Scholpp, S., Lohs, C
    5293 Erratum Engrailed and Fgf8 act synergistically to maintain the boundary between diencephalon and mesencephalon Scholpp, S., Lohs, C. and Brand, M. Development 130, 4881-4893. An error in this article was not corrected before going to press. Throughout the paper, efna4 should be read as EphA4, as the authors are referring to the gene encoding the ephrin A4 receptor (EphA4) and not to that encoding its ligand ephrin A4. We apologise to the authors and readers for this mistake. Research article 4881 Engrailed and Fgf8 act synergistically to maintain the boundary between diencephalon and mesencephalon Steffen Scholpp, Claudia Lohs and Michael Brand* Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany Department of Genetics, University of Dresden (TU), Pfotenhauer Strasse 108, 01307 Dresden, Germany *Author for correspondence (e-mail: [email protected]) Accepted 23 June 2003 Development 130, 4881-4893 © 2003 The Company of Biologists Ltd doi:10.1242/dev.00683 Summary Specification of the forebrain, midbrain and hindbrain However, a patch of midbrain tissue remains between the primordia occurs during gastrulation in response to signals forebrain and the hindbrain primordia in such embryos. that pattern the gastrula embryo. Following establishment This suggests that an additional factor maintains midbrain of the primordia, each brain part is thought to develop cell fate. We find that Fgf8 is a candidate for this signal, as largely independently from the others under the influence it is both necessary and sufficient to repress pax6.1 and of local organizing centers like the midbrain-hindbrain hence to shift the DMB anteriorly independently of the boundary (MHB, or isthmic) organizer.
    [Show full text]
  • Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum
    The Journal of Neuroscience, June 15, 1999, 19(12):4962–4971 Ephrin-A Binding and EphA Receptor Expression Delineate the Matrix Compartment of the Striatum L. Scott Janis, Robert M. Cassidy, and Lawrence F. Kromer Department of Cell Biology and Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007 The striatum integrates limbic and neocortical inputs to regulate matrix neurons. In situ hybridization for EphA RTKs reveals that sensorimotor and psychomotor behaviors. This function is de- the two different ligand binding patterns strictly match pendent on the segregation of striatal projection neurons into the mRNA expression patterns of EphA4 and EphA7. anatomical and functional components, such as the striosome Ligand–receptor binding assays indicate that ephrin-A1 and and matrix compartments. In the present study the association ephrin-A4 selectively bind EphA4 but not EphA7 in the lysates of ephrin-A cell surface ligands and EphA receptor tyrosine of striatal tissue. Conversely, ephrin-A2, ephrin-A3, and kinases (RTKs) with the organization of these compartments ephrin-A5 bind EphA7 but not EphA4. These observations im- was determined in postnatal rats. Ephrin-A1 and ephrin-A4 plicate selective interactions between ephrin-A molecules and selectively bind to EphA receptors on neurons restricted to the EphA RTKs as potential mechanisms for regulating the com- matrix compartment. Binding is absent from the striosomes, partmental organization of the striatum. which were identified by m-opioid
    [Show full text]
  • Inhibition of Metastasis by HEXIM1 Through Effects on Cell Invasion and Angiogenesis
    Oncogene (2013) 32, 3829–3839 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis W Ketchart1, KM Smith2, T Krupka3, BM Wittmann1,7,YHu1, PA Rayman4, YQ Doughman1, JM Albert5, X Bai6, JH Finke4,YXu2, AA Exner3 and MM Montano1 We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF-1a protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory pro- angiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Rabbit Anti-Ephrin-A1 Rabbit Anti-Ephrin-A1
    Qty: 100 µg/400 µl Rabbit anti-ephrin-A1 Catalog No. 34-3300 Lot No. See product label Rabbit anti-ephrin-A1 FORM This polyclonal antibody is supplied as a 400 µl aliquot at a concentration of 0.25 mg/ml in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. The antibody is epitope-affinity-purified from rabbit antiserum. PAD: ZMD.39 IMMUNOGEN Synthetic peptide derived from the C-terminal end of mouse ephrin-A1 protein. SPECIFICITY This antibody is specific for the ephrin-A1 protein. REACTIVITY Reactivity is confirmed with a chimeric protein consisting of the extracellular domain of mouse ephrin-A1 and the Fc region of human IgG1. Cross-reactivity with human ephrin-A1 is confirmed with IHC experiments on human tissue sections and this reactivity was expected because of the 85% shared amino acid identity in the extracellular domain. Sample Western Immunoprecipitation Immunohistochemistry Blotting (FFPE) Mouse +++ +++ NT Human NT NT ++ (Excellent +++, Good++, Poor +, No reactivity 0, Not tested NT) USAGE Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. Western Blotting: 1-5 µg/mL Immunoprecipitation: 5-10 µg/ IP reaction Immunohistochemistry: 4-10 µg/mL Please note that immunohistochemical assays were optimized on formalin-fixed, paraffin-embedded tissue sections and Heat Induced Epitope Retrieval (HIER) with EDTA, pH 8.0 was required for optimal staining.
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]
  • Ephrin A4-Ephrin Receptor A10 Signaling Promotes Cell Migration
    www.nature.com/scientificreports OPEN Ephrin A4‑ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells Yu‑Lin Chen1, Yi‑Chen Yen1, Chuan‑Wei Jang1, Ssu‑Han Wang1, Hsin‑Ting Huang1, Chung‑Hsing Chen2,3, Jenn‑Ren Hsiao4, Jang‑Yang Chang1 & Ya‑Wen Chen1,5* Ephrin type‑A receptor 10 (EPHA10) has been implicated as a potential target for breast and prostate cancer therapy. However, its involvement in oral squamous cell carcinoma (OSCC) remains unclear. We demonstrated that EPHA10 supports in vivo tumor growth and lymphatic metastasis of OSCC cells. OSCC cell migration, epithelial mesenchymal transition (EMT), and sphere formation were found to be regulated by EPHA10, and EPHA10 was found to drive expression of some EMT‑ and stemness‑ associated transcription factors. Among EPHA10 ligands, exogenous ephrin A4 (EFNA4) induced the most OSCC cell migration and sphere formation, as well as up‑regulation of SNAIL, NANOG, and OCT4. These efects were abolished by extracellular signal‑regulated kinase (ERK) inhibition and NANOG knockdown. Also, EPHA10 was required for EFNA4‑induced cell migration, sphere formation, and expression of NANOG and OCT4 mRNA. Our microarray dataset revealed that EFNA4 mRNA expression was associated with expression of NANOG and OCT4 mRNA, and OSCC patients showing high co‑expression of EFNA4 with NANOG or OCT4 mRNA demonstrated poor recurrence‑free survival rates. Targeting forward signaling of the EFNA4‑EPHA10 axis may be a promising therapeutic approach for oral malignancies, and the combination of EFNA4 mRNA and downstream gene expression may be a useful prognostic biomarker for OSCC.
    [Show full text]
  • Neurod Family Transcription Factors Regulate Corpus Callosum Formation and Cell Differentiation During Cerebral Cortical Development
    Aus dem Institut für Cell und Neurobiologie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION NeuroD Family Transcription Factors Regulate Corpus Callosum Formation and Cell Differentiation during Cerebral Cortical Development zur Erlangung des akademischen Grades Doctor of Philosophy (PhD) Im Rahmen des International Graduate Program Medical Neurosciences vorgelegt der Medizinischen Fakultät Charité – Universitätsmedizin Berlin von Kuo Yan aus: Jinan, China Datum der Promotion: 5. Juni 2016 1 Table of Contents Abstract .................................................................................................................... 5 Zusammenfassung .................................................................................................. 7 1. Introduction ......................................................................................................... 9 1.1 Cerebral cortex development ………………………………………...................... 9 1.1.1 Layering and wiring of the neocortex ........................................................... 9 1.1.2 Formation of the corpus callosum ................................................................ 12 1.2 Basic helix-loop-helix transcription factors ........................................................ 13 1.2.1 NeuroD family transcription factors .............................................................. 14 1.2.2 NeuroD2/6 double deficient mice as a model for axogenesis study ............ 15 1.3 Ephrin-Eph signaling ........................................................................................
    [Show full text]
  • Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions
    Oncogene (2019) 38:6567–6584 https://doi.org/10.1038/s41388-019-0931-2 REVIEW ARTICLE Eph receptor signalling: from catalytic to non-catalytic functions 1,2 1,2 3 1,2 1,2 Lung-Yu Liang ● Onisha Patel ● Peter W. Janes ● James M. Murphy ● Isabelle S. Lucet Received: 20 March 2019 / Revised: 23 July 2019 / Accepted: 24 July 2019 / Published online: 12 August 2019 © The Author(s) 2019. This article is published with open access Abstract Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that 1234567890();,: 1234567890();,: drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6.
    [Show full text]